Literature DB >> 9660103

BDNF and TrkB expression in intrastriatal ventral mesencephalic grafts in a rat model of Parkinson's disease.

J Sautter1, M Sabel, C Sommer, S Strecker, N Weidner, W H Oertel, M Kiessling.   

Abstract

We investigated the expression of BDNF and its high affinity receptor trkB in fetal dopaminergic grafts in a rat model of Parkinson's disease. Grafts were allowed to differentiate for 7, 14, 28, or 56 days, respectively and were analyzed immunocytochemically thereafter with antibodies directed against tyrosine hydroxylase, BDNF and trkB. At all time points investigated, grafts contained tyrosine hydroxylase immunoreactive neurons. Immature grafts (7 days) displayed no immunoreactivity for BDNF which was restricted to glial cells at the graft-host interface. After longer differentiation periods BDNF-immunoreactivity was detectable in neurons and astrocytes within the grafts. No trkB immunoreactivity was found in immature grafts but a strong signal for trkB emerged in grafted neurons older than 14 days whereas glial cells remained unlabeled at all time points investigated. Expression of BDNF and trkB in grafted neurons and of BDNF in surrounding glial cells suggests an autocrine or paracrine action of BDNF on dopaminergic neurons possibly mediated by activated glia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660103     DOI: 10.1007/s007020050054

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  2 in total

1.  Epibranchial placode-derived neurons produce BDNF required for early sensory neuron development.

Authors:  Danielle E Harlow; Hui Yang; Trevor Williams; Linda A Barlow
Journal:  Dev Dyn       Date:  2011-01-05       Impact factor: 3.780

2.  Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons.

Authors:  Brian T Terpstra; Timothy J Collier; Deanna M Marchionini; Nathan D Levine; Katrina L Paumier; Caryl E Sortwell
Journal:  J Neurosci Methods       Date:  2007-07-01       Impact factor: 2.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.